Loading…

PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control

The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTE...

Full description

Saved in:
Bibliographic Details
Published in:Genes & cancer 2010-12, Vol.1 (12), p.1170-1177
Main Author: Georgescu, Maria-Magdalena
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3
cites
container_end_page 1177
container_issue 12
container_start_page 1170
container_title Genes & cancer
container_volume 1
creator Georgescu, Maria-Magdalena
description The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTEN tumor suppressor is the major brake of the pathway and a common target for inactivation in somatic cancers. This review will highlight the networking of PTEN with other inhibitors of the pathway, relevant to cancer progression. PTEN constitutes the main node of the inhibitory network, and a series of convergences at different levels in the PI3K-Akt pathway, starting from those with growth factor receptors, will be described. As PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP(3)) phosphatase, thus opposing the activity of PI3K, the concerted actions to increase the availability of PIP(3) in cancer cells, relying either on other phosphoinositide enzymes or on the intrinsic regulation of PTEN activity by other molecules, will be discussed. In particular, the synergy between PTEN and the circle of its direct interacting proteins will be brought forth in an attempt to understand both the activation of the PI3K-Akt pathway and the connections with other parallel oncogenic pathways. The understanding of the interplay between the modulators of the PI3K-Akt pathway in cancer should eventually lead to the design of therapeutic approaches with increased efficacy in the clinic.
doi_str_mv 10.1177/1947601911407325
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3092286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>878820636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3</originalsourceid><addsrcrecordid>eNpdUMFOwkAQ3RiNGOTuyfTmqTq70267FxNCUIkEScTzZmm3Umm7uNtK-HvbgESdy7zMzHtv8gi5onBLaRTdURFEHKigNIAIWXhCLrqRz4FFp0dMRY8MnPuAthCB8_Cc9FjLF0EAF0TMF-OZt2hKY73XZrOx2rkWznS9NXbt5ZU3n-CzP1zX3lzVq63aeSNT1dYUl-QsU4XTg0Pvk7eH8WL05E9fHiej4dRPkELoB4nKUDEdiAhSnolUJx1YxiHDEOIgDAAUV8hi1JAqBZgJipSnodbIdYZ9cr_X3TTLUqeJbt1VITc2L5XdSaNy-XdT5Sv5br4kgmAs5q3AzUHAms9Gu1qWuUt0UahKm8bJOIpjBhy7S9hfJtY4Z3V2dKEgu8zl_8xbyvXv746En4TxGyNSeq4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>878820636</pqid></control><display><type>article</type><title>PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control</title><source>PubMed (Medline)</source><creator>Georgescu, Maria-Magdalena</creator><creatorcontrib>Georgescu, Maria-Magdalena</creatorcontrib><description>The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTEN tumor suppressor is the major brake of the pathway and a common target for inactivation in somatic cancers. This review will highlight the networking of PTEN with other inhibitors of the pathway, relevant to cancer progression. PTEN constitutes the main node of the inhibitory network, and a series of convergences at different levels in the PI3K-Akt pathway, starting from those with growth factor receptors, will be described. As PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP(3)) phosphatase, thus opposing the activity of PI3K, the concerted actions to increase the availability of PIP(3) in cancer cells, relying either on other phosphoinositide enzymes or on the intrinsic regulation of PTEN activity by other molecules, will be discussed. In particular, the synergy between PTEN and the circle of its direct interacting proteins will be brought forth in an attempt to understand both the activation of the PI3K-Akt pathway and the connections with other parallel oncogenic pathways. The understanding of the interplay between the modulators of the PI3K-Akt pathway in cancer should eventually lead to the design of therapeutic approaches with increased efficacy in the clinic.</description><identifier>ISSN: 1947-6019</identifier><identifier>EISSN: 1947-6027</identifier><identifier>DOI: 10.1177/1947601911407325</identifier><identifier>PMID: 21779440</identifier><language>eng</language><publisher>United States: SAGE Publications</publisher><ispartof>Genes &amp; cancer, 2010-12, Vol.1 (12), p.1170-1177</ispartof><rights>The Author(s) 2011 2011 The Author(s)</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092286/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092286/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21779440$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Georgescu, Maria-Magdalena</creatorcontrib><title>PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control</title><title>Genes &amp; cancer</title><addtitle>Genes Cancer</addtitle><description>The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTEN tumor suppressor is the major brake of the pathway and a common target for inactivation in somatic cancers. This review will highlight the networking of PTEN with other inhibitors of the pathway, relevant to cancer progression. PTEN constitutes the main node of the inhibitory network, and a series of convergences at different levels in the PI3K-Akt pathway, starting from those with growth factor receptors, will be described. As PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP(3)) phosphatase, thus opposing the activity of PI3K, the concerted actions to increase the availability of PIP(3) in cancer cells, relying either on other phosphoinositide enzymes or on the intrinsic regulation of PTEN activity by other molecules, will be discussed. In particular, the synergy between PTEN and the circle of its direct interacting proteins will be brought forth in an attempt to understand both the activation of the PI3K-Akt pathway and the connections with other parallel oncogenic pathways. The understanding of the interplay between the modulators of the PI3K-Akt pathway in cancer should eventually lead to the design of therapeutic approaches with increased efficacy in the clinic.</description><issn>1947-6019</issn><issn>1947-6027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpdUMFOwkAQ3RiNGOTuyfTmqTq70267FxNCUIkEScTzZmm3Umm7uNtK-HvbgESdy7zMzHtv8gi5onBLaRTdURFEHKigNIAIWXhCLrqRz4FFp0dMRY8MnPuAthCB8_Cc9FjLF0EAF0TMF-OZt2hKY73XZrOx2rkWznS9NXbt5ZU3n-CzP1zX3lzVq63aeSNT1dYUl-QsU4XTg0Pvk7eH8WL05E9fHiej4dRPkELoB4nKUDEdiAhSnolUJx1YxiHDEOIgDAAUV8hi1JAqBZgJipSnodbIdYZ9cr_X3TTLUqeJbt1VITc2L5XdSaNy-XdT5Sv5br4kgmAs5q3AzUHAms9Gu1qWuUt0UahKm8bJOIpjBhy7S9hfJtY4Z3V2dKEgu8zl_8xbyvXv746En4TxGyNSeq4</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Georgescu, Maria-Magdalena</creator><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20101201</creationdate><title>PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control</title><author>Georgescu, Maria-Magdalena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Georgescu, Maria-Magdalena</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Genes &amp; cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Georgescu, Maria-Magdalena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control</atitle><jtitle>Genes &amp; cancer</jtitle><addtitle>Genes Cancer</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>1</volume><issue>12</issue><spage>1170</spage><epage>1177</epage><pages>1170-1177</pages><issn>1947-6019</issn><eissn>1947-6027</eissn><abstract>The PI3K-Akt pathway is a major survival pathway activated in cancer. Efforts to develop targeted therapies have not been fully successful, mainly because of extensive internal intrapathway or external interpathway negative feedback loops or because of networking between pathway suppressors. The PTEN tumor suppressor is the major brake of the pathway and a common target for inactivation in somatic cancers. This review will highlight the networking of PTEN with other inhibitors of the pathway, relevant to cancer progression. PTEN constitutes the main node of the inhibitory network, and a series of convergences at different levels in the PI3K-Akt pathway, starting from those with growth factor receptors, will be described. As PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP(3)) phosphatase, thus opposing the activity of PI3K, the concerted actions to increase the availability of PIP(3) in cancer cells, relying either on other phosphoinositide enzymes or on the intrinsic regulation of PTEN activity by other molecules, will be discussed. In particular, the synergy between PTEN and the circle of its direct interacting proteins will be brought forth in an attempt to understand both the activation of the PI3K-Akt pathway and the connections with other parallel oncogenic pathways. The understanding of the interplay between the modulators of the PI3K-Akt pathway in cancer should eventually lead to the design of therapeutic approaches with increased efficacy in the clinic.</abstract><cop>United States</cop><pub>SAGE Publications</pub><pmid>21779440</pmid><doi>10.1177/1947601911407325</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1947-6019
ispartof Genes & cancer, 2010-12, Vol.1 (12), p.1170-1177
issn 1947-6019
1947-6027
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3092286
source PubMed (Medline)
title PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A07%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PTEN%20Tumor%20Suppressor%20Network%20in%20PI3K-Akt%20Pathway%20Control&rft.jtitle=Genes%20&%20cancer&rft.au=Georgescu,%20Maria-Magdalena&rft.date=2010-12-01&rft.volume=1&rft.issue=12&rft.spage=1170&rft.epage=1177&rft.pages=1170-1177&rft.issn=1947-6019&rft.eissn=1947-6027&rft_id=info:doi/10.1177/1947601911407325&rft_dat=%3Cproquest_pubme%3E878820636%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3105-4caf3a2e4970d6f9dec70d6b852350845400a6a3283e0daa03f91316d5ee36ef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=878820636&rft_id=info:pmid/21779440&rfr_iscdi=true